ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 Phase 3 SPOTLIGHT Study Primary Results: Zolbetuximab + mFOLFOX6 as 1L Treatment for Patients With CLDN18.2+/HER2- Locally Advanced Unresectable/Metastatic Gastric or GEJ Adenocarcinoma

489 views
January 26, 2023
Comments 0
Login to view comments. Click here to Login